Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR. Charles Coombes, Judith M. Bliss, Lucy Kilburn et al.|The Lancet|2007Cited by 912
AT (doxorubicin-Taxol) versus AC (doxorubicin-cyclophosphamide) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. (originally presented at ASCO 2000. Abstract 282)M. Piccart, Ron Epelbaum, T. Čufer et al.|Ghent University Academic Bibliography (Ghent University)|2000Cited by 15
0132 The effect of zoledronic acid in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months integrated follow-up of the Z-FAST/ZO-FAST trialsAntonio Frassoldati, RE Coleman, Adam Brufsky et al.|The Breast|2009Cited by 5
Abstract OT1-04-04: A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor–positive breast cancer patients with bone metastasesRE Coleman, HS Rugo, Georgeta Fried et al.|Cancer Research|2017Cited by 2
Abstract P1-05-01: Breast cancer cell-derived IL-1B drives metastasis and colonisation of the bone microenvironmentPenelope D. Ottewell, Claudia Tulotta, Victoria Cookson et al.|Cancer Research|2019Cited by 2